Top

Published in:

01-01-2010 | Preclinical Study

Expression of Gli1 correlates with the transition of breast cancer cells to estrogen-independent growth

Authors: Jieying Zhao, Guangchun Chen, Dongmei Cao, Yidong Li, Fei Diao, Haoyu Cai, Yiduo Jin, Jian Lu

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Abstract

The failure of breast cancer treatment is largely due to the development of estrogen independence. Current data illustrate that Hedgehog (Hh) signaling may play an important role in breast cancer development. Here, we show that the expression of the Hh effector protein, Gli1 was significantly higher in estrogen-independent breast cancer cells than in estrogen-dependent cells. Our data showed for the first time that stable expression of Gli1 in ER positive breast cancer cell lines MCF-7 and T47D can induce estrogen-independent proliferation and promote G1/S phase transition, which associated with cyclin-Rb axi. Gli1 can also attenuate the response of proliferation to estrogenic stimulation, which was correlated with down-regulation of expression of ERα and PR, as well as down-regulation of transactivation of ERα. Our results suggest that up-regulation of Gli1 in breast cancer cells may be one of the mechanisms responsible for developing estrogen independence and this process may be regulated through down-regulation of expression and transactivation of ERα.

Available only for authorised users

Allred DC, Brown P, Medina D (2004) The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 6:240–245. doi:10.1186/bcr938 CrossRefPubMed

Normanno N, Di Maio M, De Maio E et al (2005) Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12:721–747. doi:10.1677/erc.1.00857 CrossRefPubMed

Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423. doi:10.1073/pnas.0932692100 CrossRefPubMed

Bhat-Nakshatri P, Sweeney CJ, Nakshatri H (2002) Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene 21:2066–2078. doi:10.1038/sj.onc.1205243 CrossRefPubMed

Glidewell-Kenney C, Weiss J, Lee EJ et al (2005) ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol 245:53–59. doi:10.1016/j.mce.2005.10.003 CrossRefPubMed

Nakshatri H, Bhat-Nakshatri P, Martin DA et al (1997) Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629–3639PubMed

Pratt MA, Bishop TE, White D et al (2003) Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol Cell Biol 23:6887–6900. doi:10.1128/MCB.23.19.6887-6900.2003 CrossRefPubMed

Zhou Y, Eppenberger-Castori S, Eppenberger U et al (2005) The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 12(Suppl 1):S37–S46. doi:10.1677/erc.1.00977 CrossRefPubMed

Hooper JE, Scott MP (2005) Communicating with Hedgehogs. Nat Rev Mol Cell Biol 6:306–317. doi:10.1038/nrm1622 CrossRefPubMed

10.

Ingham PW, McMahon AP (2001) Hedgehog signaling in animal development: paradigms and principles. Genes Dev 15:3059–3087. doi:10.1101/gad.938601 CrossRefPubMed

11.

Murone M, Rosenthal A, de Sauvage FJ (1999) Hedgehog signal transduction: from flies to vertebrates. Exp Cell Res 253:25–33. doi:10.1006/excr.1999.4676 CrossRefPubMed

12.

Pasca di Magliano M, Hebrok M (2003) Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 3:903–911. doi:10.1038/nrc1229 CrossRefPubMed

13.

Ruiz i Altaba A (1999) Gli proteins encode context-dependent positive and negative functions: implications for development and disease. Development 126:3205–3216PubMed

14.

Ruiz i Altaba A, Sanchez P, Dahmane N (2002) Gli and hedgehog in cancer: tumours, embryos, and stem cells. Nat Rev Cancer 2:361–372. doi:10.1038/nrc796 CrossRefPubMed

15.

Kinzler KW, Bigner SH, Bigner DD et al (1987) Identification of an amplified, highly expressed gene in a human glioma. Science 236:70–73. doi:10.1126/science.3563490 CrossRefPubMed

16.

Lee J, Platt KA, Censullo P et al (1997) Gli1 is a target of Sonic hedgehog that induces ventral neural tube development. Development 124:2537–2552PubMed

17.

Lauth M, Toftgard R (2007) Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. Cell Cycle 6:2458–2463PubMed

18.

Fiaschi M, Rozell B, Bergstrom A et al (2007) Targeted expression of GLI1 in the mammary gland disrupts pregnancy-induced maturation and causes lactation failure. J Biol Chem 282:36090–36101. doi:10.1074/jbc.M704280200 CrossRefPubMed

19.

Hatsell S, Frost AR (2007) Hedgehog signaling in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 12:163–173. doi:10.1007/s10911-007-9048-2 CrossRefPubMed

20.

Hatsell SJ, Cowin P (2006) Gli3-mediated repression of Hedgehog targets is required for normal mammary development. Development 133:3661–3670. doi:10.1242/dev.02542 CrossRefPubMed

21.

Lewis MT, Ross S, Strickland PA et al (2001) The Gli2 transcription factor is required for normal mouse mammary gland development. Dev Biol 238:133–144. doi:10.1006/dbio.2001.0410 CrossRefPubMed

22.

Lewis MT, Ross S, Strickland PA et al (1999) Defects in mouse mammary gland development caused by conditional haploinsufficiency of Patched-1. Development 126:5181–5193PubMed

23.

Lewis MT, Visbal AP (2006) The hedgehog signaling network, mammary stem cells, and breast cancer: connections and controversies. Ernst Schering Found Symp Proc 5:181–217. doi:10.1007/2789_2007_051 CrossRefPubMed

24.

Liu S, Dontu G, Mantle ID et al (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66:6063–6071. doi:10.1158/0008-5472.CAN-06-0054 CrossRefPubMed

25.

Moraes RC, Zhang X, Harrington N et al (2007) Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation, and ductal dysplasia. Development 134:1231–1242. doi:10.1242/dev.02797 CrossRefPubMed

26.

Park HL, Bai C, Platt KA et al (2000) Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. Development 127:1593–1605PubMed

27.

Hu Z, Bonifas JM, Aragon G et al (2003) Evidence for lack of enhanced hedgehog target gene expression in common extracutaneous tumors. Cancer Res 63:923–928PubMed

28.

Kubo M, Nakamura M, Tasaki A et al (2004) Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 64:6071–6074. doi:10.1158/0008-5472.CAN-04-0416 CrossRefPubMed

29.

Mukherjee S, Frolova N, Sadlonova A et al (2006) Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther 5:674–683PubMedCrossRef

30.

Koga K, Nakamura M, Nakashima H et al (2008) Novel link between estrogen receptor alpha and hedgehog pathway in breast cancer. Anticancer Res 28:731–740PubMed

31.

Zhang X, Harrington N, Moraes RC, et al. (2008) Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat. doi:10.1007/s10549-008-0093-3

32.

Wolf I, Bose S, Desmond JC et al (2007) Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer. Breast Cancer Res Treat 105:139–155. doi:10.1007/s10549-006-9440-4 CrossRefPubMed

33.

Jansson A, Gunnarsson C, Stal O (2006) Proliferative responses to altered 17beta-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors. Endocr Relat Cancer 13:875–884. doi:10.1677/erc.1.01181 CrossRefPubMed

34.

Madureira PA, Varshochi R, Constantinidou D et al (2006) The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J Biol Chem 281:25167–25176. doi:10.1074/jbc.M603906200 CrossRefPubMed

35.

Freund A, Chauveau C, Brouillet JP et al (2003) IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 22:256–265. doi:10.1038/sj.onc.1206113 CrossRefPubMed

36.

Vladusic EA, Hornby AE, Guerra-Vladusic FK et al (2000) Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. Oncol Rep 7:157–167PubMed

37.

Buckley MF, Sweeney KJ, Hamilton JA et al (1993) Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127–2133PubMed

38.

Tam SW, Theodoras AM, Shay JW et al (1994) Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression. Oncogene 9:2663–2674PubMed

39.

Lukas J, Bartkova J, Welcker M et al (1995) Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene 10:2125–2134PubMed

40.

Sweeney KJ, Sarcevic B, Sutherland RL et al (1997) Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene 14:1329–1340. doi:10.1038/sj.onc.1200951 CrossRefPubMed

41.

Evron E, Umbricht CB, Korz D et al (2001) Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 61:2782–2787PubMed

42.

Mitas M, Almeida JS, Mikhitarian K et al (2005) Accurate discrimination of Barrett’s esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. Clin Cancer Res 11:2205–2214. doi:10.1158/1078-0432.CCR-04-1091 CrossRefPubMed

Title: Expression of Gli1 correlates with the transition of breast cancer cells to estrogen-independent growth
Authors: Jieying Zhao
Guangchun Chen
Dongmei Cao
Yidong Li
Fei Diao
Haoyu Cai
Yiduo Jin
Jian Lu
Publication date: 01-01-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0323-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

Controversial BRCA1 allelotypes in commonly used breast cancer cell lines

Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer

Bisphosphonate-related osteonecrosis of the jaw in randomized clinical trials

The impact of sociodemographic, treatment, and work support on missed work after breast cancer diagnosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer